RecruitingNot applicableNCT06967051
The Efficacy of a Smart Phone-based Test on Measuring Pupillary Light Reflex Alterations Following Cannabis Use Healthy in Adults
Studying Primary orthostatic tremor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sobereye Inc.
- Principal Investigator
- David Crowley, MDKGK Science Inc.
- Intervention
- Tetrahydrocannabinol (10 mg)(drug)
- Enrollment
- 20 target
- Eligibility
- 21 years · All sexes
- Timeline
- 2025 – 2025
Study locations (1)
- KGK Science Inc., London, Ontario, Canada
Collaborators
KGK Science Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06967051 on ClinicalTrials.govOther trials for Primary orthostatic tremor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07340554Neuroimaging of Adolescent Cannabis Use TreatmentIndiana University
- ACTIVE NOT RECRUITINGNCT07582445Perioperative Prospective Follow Up Of Cannabis Consumers and Discrepancy UseHadassah Medical Organization
- RECRUITINGPHASE2NCT07523633Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use DisorderAnders Fink-Jensen, MD, DMSci
- ENROLLING BY INVITATIONNANCT07513337Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes (Aim 2 Study)Johns Hopkins Bloomberg School of Public Health
- RECRUITINGNANCT07056894Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase PsychosisNova Scotia Health Authority
- RECRUITINGNANCT07196462Precision Brain Stimulation to Reduce Cannabis Craving in SchizophreniaVanderbilt University Medical Center
- RECRUITINGPHASE3NCT05052541Safety and Efficacy of Oral Cannabis in Chronic Spine PainUniversity of Colorado, Denver
- RECRUITINGPHASE1NCT07176208Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy AdultsFood and Drug Administration (FDA)